Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

All cancers emerge after a period of clonal selection and subsequent clonal expansion.
Although the evolutionary principles imparted by genetic intratumour heterogeneity are …

An incomplete view of the mechanisms that drive metastasis, the primary cause of cancer-
related death, has been a major barrier to development of effective therapeutics and …

Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-
like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are …

Therapy resistance arises from heterogeneous drug-tolerant persister cells or minimal
residual disease (MRD) through genetic and nongenetic mechanisms. A key question is …